Advertisement

 

 

Stability of 5P12-RANTES, a candidate rectal microbicide, in human rectal lavage.

Stability of 5P12-RANTES, a candidate rectal microbicide, in human rectal lavage.
Author Information (click to view)

Cerini F, Offord RE, McGowan I, Hartley O,


Cerini F, Offord RE, McGowan I, Hartley O, (click to view)

Cerini F, Offord RE, McGowan I, Hartley O,

Advertisement

AIDS research and human retroviruses 2017 02 08() doi 10.1089/AID.2016.0199

Abstract

In the absence of an effective vaccine, strategies to prevent HIV transmission are urgently needed. Condomless receptive anal intercourse represents a major route of transmission, and efforts are being made to develop strategies in which potent anti-HIV drugs are formulated for topical application to the rectum prior to sex. 5P12-RANTES is a promising candidate for such a purpose. It is an analogue of the human chemokine RANTES/CCL5, which potently blocks CCR5, the principal coreceptor used by HIV to enter and infect target cells. As a protein, 5P12-RANTES is potentially vulnerable to attack by proteases in the rectal environment. Here we tested the stability of 5P12-RANTES on exposure to rectal lavage samples obtained from healthy volunteers, using a sensitive HIV entry inhibition assay as an indicator of stability. Varying levels of inactivating activity towards 5P12-RANTES were detected across the different lavage samples. Analysis of even the most aggressive samples indicated that protease activity in the rectal environment is unlikely to impact on the anti-HIV activity of 5P12-RANTES when applied pericoitally at the envisaged clinical dose (1 mM). This study indicates that 5P12-RANTES has adequate stability for further development as an HIV prevention drug for rectal use.

Submit a Comment

Your email address will not be published. Required fields are marked *

13 − 12 =

[ HIDE/SHOW ]